



Vienna (CET)	Day 1 January 28	Day 2 January 29			Day 3 January 30			Day 4 January 31		
		Antibody	Immunotherapy	Locoregional/Oligo	Immuno-Biology	Screening/ED	Nursing/AHP	Palliative Care	Risk Reduction and Tobacco Control	Staging
		Health Services	Diagnostic/Pulmonology and Targeted Therapies	Early Stage	Pathology	Mesothelioma	Patient Advocacy	Targeted Therapies	SCLC/NET	Tumor Biology
24:00 - 02:00	Joint IASLC-CAALC-CSCO Session*	PL02: Innovation to Bridge Lung Cancer Care Tomorrow			PS01: Presidential Symposium			PL04: A Vision for Clinical Trials in 2020 and Beyond		
		Live Q&A			Live Q&A			Live Q&A		
02:15 - 03:15	IS01: Satellite CME Symposium by Clinical Care Options**	ES01: Choosing Systemic Therapies After Chemoimmunotherapy in NSCLC	OA01: Established Drugs in Special Populations and New Drugs in Established Populations	OA02: Updates in Locally Advanced NSCLC	ES09: Biomarkers in Immunotherapy	ES10: Advances in Lung Cancer Screening Through Imaging and Data Analytics	ES11: Practice-Changing Initiatives	ES20: Evidence Base for Symptom Management	ES21: The "How To" of Modern Tobacco Control	MA09: Prognosis and Staging
		Live Q&A		Live Q&A	Live Q&A		Live Q&A	Live Q&A		Live Q&A
03:30 - 04:30	IS02: Industry Symposium*	OA03: Promising Antibody-Drug Conjugate and Cytotoxic Therapy in NSCLC	ES02: Pro-Con: Do We Need Biomarkers to Guide the Choice of Immunotherapy Treatment?	ES03: Understanding and Treating Oligometastatic Diseases	OA07: Immuno-biology and Novel Immunotherapeutics from Bench to Bed	ES12: Public Health Issues in Lung Cancer Screening		ES22: Quality of Life	OA10: The Slow Pandemic - Tobacco Control in the Prevention of Lung Cancer	ES23: Beyond the TNM
		Live Q&A		Live Q&A	Live Q&A			Live Q&A		Live Q&A
04:45 - 05:45	IS03: Industry Symposium*	MA01: Novel Systemic Treatment in NSCLC	OA04: New Data from Rare EGFR Alterations	ES04: Strategies to Increase Cure Rates in Stage III NSCLC: Optimising Checkpoint Inhibitors and Beyond	ES14: Novel Immunotherapy Strategies in NSCLC	MA05: Lung Cancer Screening	OA08: Putting the Patient at the Center: Holistic Patient Care	MA10: Assessing and Managing Supportive Care Needs	ES24: Challenges in Tobacco Control	ES25: Unmet Need Issues of Current TNM
		Live Q&A		Live Q&A	Live Q&A		Live Q&A	Live Q&A		Live Q&A
06:00 - 07:00	IS04: Industry Symposium*	IS08: Industry Symposium*	IS09: Industry Symposium*	IS10: Industry Symposium*	IS11: Industry Symposium*	IS12: Industry Symposium*		IS13: Satellite CPD Symposium by ACE Oncology**	IS14: Industry Symposium*	IS15: Industry Symposium*
		ES05: Value in Lung Cancer, from Screening to Treatment	MA02: Technological Advances in Diagnostics, Imaging and Therapeutics for Lung Cancer	ES06: Perioperative Therapy for Early Stage NSCLC	ES15: Getting All NSCLCs Genotyped: How Can We Get to 100%?	MA06: Molecular Developments and Novel Treatments in Mesothelioma and Thymoma	ES16: Joint Global Lung Cancer Coalition/IASLC Session: Hot Topics for Advocates	MA11: Expanding Targetable Genetic Alterations in NSCLC	ES26: Future Horizons in the Management of Small Cell Lung Cancer	ES27: Heterogeneity, Metastases and Resistance
		Live Q&A		Live Q&A	Live Q&A		Live Q&A	Live Q&A		Live Q&A
08:30 - 09:30	IS06: Industry Symposium*	OA05: Value and Quality in Lung Cancer	ES07: Pleural Effusion in a Cancer Patient	MA03: New and Revisited Factors in Early Stage Lung Cancer	ES17: The New WHO Classification of Lung Tumors	OA09: Mesothelioma from Pathogenesis to Therapy	MA07: Improving Care for People with Lung Cancer: Decision Making, Survivorship, and New Challenges During COVID-19	ES28: Targeting KRAS	OA11: A Symphony of Progress	ES29: Advances in Omics - Next Generation
		Live Q&A		Live Q&A	Live Q&A		Live Q&A	Live Q&A		Live Q&A
09:45 - 10:45	IS07: Industry Symposium*	MA04: Health Policy and the Real World	ES08: The Solitary Pulmonary Nodule	OA06: Updates on EGFR Targeted Perioperative Therapy and Precision Adjuvant Chemotherapy	MA08: Advances in Biomarkers for Immune Checkpoint Blockade and Targeted Therapy in Non-Small Cell Lung Carcinoma	ES18: The Future of Immunotherapy in Unresectable Mesothelioma	ES19: Patient-Reported Outcomes, Patient Registries and Real-World Evidence: Learning Directly from Patients	ES30: What is the Best Treatment Strategy to Target Rare Mutations	MA12: Controversies Old and New	MA13: Tumor Biology: Focus on EGFR Mutation, DNA Repair and Tumor Microenvironment
		Live Q&A		Live Q&A	Live Q&A		Live Q&A	Live Q&A		Live Q&A
11:00 - 13:00	PL01: Opening Plenary Session	PL03: Bench to Bedside (Immunology)			PS02: Presidential Symposium (Rebroadcasted)			PL05: Affordable and Accessible Lung Cancer Care		
		Live Q&A			Live Q&A			Live Q&A		

PL - Plenary

PS - Presidential Symposium

ES - Education Session

OA - Oral Session

MA - Mini Oral Session

IS - Industry Symposium, Satellite CME Symposium or Satellite CDP Symposium

★ IASLC CME Accredited

☆ CME or CPD Accredited by Other Provider

\*Not for CME Credit, see page 2 for more details for more information about the Industry Symposium sessions.

\*\*CME or CDP Accredited by Other Provider, see page 2 for more details.

